Eli Lilly & Company (NYSE:LLY) | Lilly for Better Health™ expands website’s non-product-branded health education resources, focuses on healthy behavior skills

Eli Lilly & Company (NYSE:LLY) [PR Newswire] – INDIANAPOLIS, July 10, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) has rebooted the Lilly for Better Health™ program, with several innovative enhancements to lillyforbetterhealth.com that help enrich the user experience with Lilly’s non-product-branded health education. Lilly for Better Health is one of the many ways Lilly goes beyond medicine to support individuals and caregivers on their health care journeys. The program, and its website, lillyforbetterhealth.com, recognized by the MarCom Awards, Aster Awards and eHealthcare for excellence in health communication, offer nearly 100 non-product-branded health education resources in English and Spanish, plus information on health-related topics, such as diabetes, depression, exercise and stress.
Read more on this.

Eli Lilly and Company (LLY), valued at $67.17B, started trading this morning at $62.13.
Looking at the equity, the company’s one day range is $61.98 to $62.71 with a trailing 52-week range being $47.53 to $63.38.
Lilly (LLY) shares are currently priced at 22.47x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -6.58x earnings multiple for the same period.
And for passive income investors, the company pays shareholders $1.96 per share annually in dividends, yielding 3.20%.
According to a consensus of 14 analysts, the earnings estimate of $0.65 per share would be $0.51 worse than the year-ago quarter and a $0.01 sequential decrease. The full-year EPS estimate is $2.78, which would be a $1.37 better than last year.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.88 Billion. If realized, that would be a 17.71% decrease over the year-ago quarter.
In terms of ratings, MKM Partners downgraded LLY from Buy to Neutral (Apr 23, 2014). Previously, Barclays downgraded LLY from Equal Weight to Underweight.
When considering if perhaps the stock is under or overvalued, the average price target is $61.82, which is 0.50% below where the stock opened this morning.
Summary (NYSE:LLY) :  Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Tag Helper ~ Stock Code: LLY | Common Company name: Lilly | Full Company name: Eli Lilly & Company (NYSE:LLY) .

Share the News | facebooktwittergoogle_plusredditlinkedin |

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles

Click for a Random Article: [This Month] | [This Year] | [All Time]

Comments are closed.